Rivoceranib
- Generic Name
- Rivoceranib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C24H23N5O
- CAS Number
- 811803-05-1
- Unique Ingredient Identifier
- 5S371K6132
- Background
Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).
- Indication
本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2018-08-15
- Lead Sponsor
- Zhengzhou University
- Target Recruit Count
- 100
- Registration Number
- NCT03631862
- Locations
- 🇨🇳
Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2018-08-09
- Target Recruit Count
- 40
- Registration Number
- NCT03609489
- Locations
- 🇨🇳
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 45
- Registration Number
- NCT03603756
- Locations
- 🇨🇳
Jing Huang, Beijing, China
Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 288
- Registration Number
- NCT03598348
- Locations
- 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China
XELOX Combined With Apatinib as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT03599778
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital, Hefei, Anhui, China
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
- First Posted Date
- 2018-07-16
- Last Posted Date
- 2020-08-05
- Target Recruit Count
- 1
- Registration Number
- NCT03587129
- Locations
- 🇨🇳
The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2021-07-09
- Lead Sponsor
- Hebei Medical University Fourth Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03580395
- Locations
- 🇨🇳
Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, Hebei, China
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2018-06-25
- Last Posted Date
- 2020-03-03
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03567135
- Locations
- 🇨🇳
Fuzhou General Hospital, Fuzhou, Fujian, China
Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Anhui Provincial Hospital
- Target Recruit Count
- 69
- Registration Number
- NCT03547375
A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Pretreated Patients With Advanced Small Cell Lung Cancer
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2020-12-01
- Lead Sponsor
- The First Hospital of Jilin University
- Target Recruit Count
- 31
- Registration Number
- NCT03547804
- Locations
- 🇨🇳
The First Hospital Of Jilin University, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.